Table 7 QALY for each screening strategy, highlighting differences by metastatic and non-metastatic stage
QALY | ||
|---|---|---|
32 months current strategy | metastatic | 10.3 (10.0-10.7) |
non-metastatic | 50.6 (50.2–51.0) | |
22-months strategy | metastatic | 12.0 (11.7–12.3) |
non-metastatic | 84.4 (84.4–84.5) | |
16-months strategy | metastatic | 9.0 (8.8–9.2) |
non-metastatic | 129.4 (129.1-129.8) |